Unicycive plummets following second CRL for OLC for hyperphosphatemia
Seeking Alpha ·
Unicycive Therapeutics is down ~37% in Tuesday afternoon trading after announcing it has received a Complete Response Letter from the FDA for its resubmitted NDA for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
DYAX Investor Sentiment
Bullish (Long) 60% · Bearish (Short) 40%
308 participants
Related News
- Scorpio Tankers cut to Sell equivalent at BofA, moving off peak cash generation
- Meta Stock Faces New AI Challenge as Google Limits Gemini Access
- AMD stock jumps, Circle plummets on stablecoin competition
- Circle Internet stock dives on new rival; Wm. Blair says 'buy'
- Gold bugs eye July as GLD enters historically strong summer window
- Amazon AWS launches new AI engineering division with $1B commitment